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Background: The Cylex immune monitoring(CIM) test represents T-cell function under immunosuppression. It has been reported that CIM can 
predict risk of infection (infn) and to a lesser degree risk of rejection after heart transplant (HTx). Recently, use of CIM to guide immunosuppression 
was shown to reduce infns in a randomized trial of liver transplant patients (pts). Similar benefit with use of CIM to guide immunotherapy after HTx 
has not been established. 
methods:  Between 8/2005 and 5/2012 we evaluated 381 HTx pts. Prior to 1/2010, 196 HTx pts’ immunosuppression was guided by 
trough drug blood levels. Following 1/2010, CIM was also used to help guide therapy for 185 pts. In general, for CIM scores <200 ATP ng/ml, 
immunosuppression was reduced with decrease in tacrolimus (TAC)/cyclosporine (CSA) or mycophenolate (MMF) dose. High CIM levels were not 
addressed. Freedom from 1st-year infn was assessed for time periods 8/2005-12/2009 and 1/2010 - 5/2012. 
results: Pts who had immunosuppression guided by CIM vs drug trough levels alone had significantly greater freedom from 1st-year infn after HTx 
(62% vs 51%, p=0.029). 1st year freedom from any-treated rejection was similar between groups. After 1/2010, for CIM scores <200, a decrease in 
immunosuppression drugs occurred 73% of the time. Two-thirds of the time MMF was reduced (by ~25%) while one-third of the time TAC/CSA was 
reduced (by ~25%). 
Endpoints
Routine Use Before 2010
(N = 196)
Guided Use After 2010
(N = 185)
p-value
1-Year Freedom from Infection, n (%) 99 (51%) 114 (62%) 0.029
1-Year Freedom from Any-Treated Rejection in Patients, n (%) 167 (85%) 168 (91%) 0.094
1-Year Survival, n (%) 180 (92%) 179 (97%) 0.040
conclusion:  The use of CIM (low scores) to guide immunosuppression in HTx appears to be beneficial to avoid risk of infection.
